All In Biotech

Drug Trial Radar · NCT07902245

Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Single-Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of RG002C0106 Injection in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 10, 2026

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if RG002C0106 is safe in healthy participants . It will also learn about how the drug is absorbed, distributed, metablized and excrited. The main questions it aims to answer are: What medical problems do participants have when taking RG002C0106? Researchers will compare RG002C0106 to a placebo (a look-alike substance that contains no drug) to see if RG002C0106 is safe to participants. Participants will: Take RG00C2C0106 or a placebo once. Visit the clinic once every 2 weeks/1 month for checkups and tests.

Conditions

  • Safety Issues

Interventions

  • RG002C0106Drug

    At Day 1, each participants will be given one dose of RG002C0106 Injection.

  • 0.9% sodium chloride injectionDrug

    At Day 1, each participants will be given one dose of 0.9% sodium chloride injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug.Time frame: within 169 days after the administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novatrials

    City of Lake Macquarie, New South Wales, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.